
Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancer
Join our daily newsletter At The Bell to receive exclusive market insights For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity Pharmaceuticals’ (ASX:CU6) news on Wednesday morning …